Portal de Periódicos da CAPES

O2‐13‐02: DIAGNOSTIC VALIDITY COMPARISON BETWEEN NIA CRITERIA FOR CSF ALZHEIMER'S DISEASE BIOMARKERS AND OTHER NEW CRITERIA

2014; Wiley; Volume: 10; Issue: 4S_Part_3 Linguagem: Inglês

10.1016/j.jalz.2014.04.229

1552-5279

Antonio Monge‐Argilés, Carlos Muñoz‐Ruiz, José Sánchez‐Payá, C. Leiva-Santana, M.E. Blanco-Cantó,

Dementia and Cognitive Impairment Research

In recent NIA criteria for Alzheimer's disease (AD) diagnosis, CSF biomarkers (BMK) have been accepted as evidence of pathophysiological process, for research purposes. Nevertheless, using it for diagnosing mild cognitive impairment (MCI) due to AD with high probability, they show a low sensitivity our objective was to compare the diagnostic validity of NIA criteria and our own new criteria, that take in account tau/Aβ proteins ratios, because they have showed their ability to predict dementia in preclinical AD. Between 2008-10, 157 MCI patients were included, after the realization of a lumbar puncture, for measuring Aβ 1-42, T-tau and P-tau 181 CSF proteins and the ratios T-tau/ Aβ 1-42 and P-tau 181/ Aβ 1-42. We used NIA and our own criteria for evaluation of AD CSF BMK results. In these lasts, we consider as high probability of MCI due to AD, when 3 or more variables were abnormal. We calculated the diagnostic validity for every criteria. After a two years follow-up, 49 MCI patients remained clinically stable, 78 developed AD and 16 developed other dementia. Using NIA criteria and our own criteria, the BMK for AD showed: sensitivity 35% versus 76%; specificity 89% versus 66%; predictive positive value 79% versus 73% and a predictive negative value of 53% versus 69%. The use of our criteria for AD CSF BMK assessment, should be interesting for early detection of AD, because they show a higher sensitivity than NIA criteria.